LLY Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $22.97B; Cost of revenue $3.27B; Research and development (m); Selling, general and administrative $3.43B.
- 2026-03-31: Revenue $19.80B; Cost of revenue $3.58B; Research and development (m); Selling, general and administrative $2.93B.
- 2025-12-31: Revenue $19.29B*; Cost of revenue $3.37B*; Research and development (m); Selling, general and administrative $3.13B*.
- 2025-09-30: Revenue $17.60B; Cost of revenue $3.01B; Research and development (m); Selling, general and administrative $2.74B.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Geography
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.97B | $3.27B | (m) | $3.43B | (m) | $2.15B | $7.09B |
| 2026-03-31 | $19.80B | $3.58B | (m) | $2.93B | (m) | $1.45B | $7.40B |
| 2025-12-31 | $19.29B* | $3.37B* | (m) | $3.13B* | (m) | $1.63B* | $6.64B* |
| 2025-09-30 | $17.60B | $3.01B | (m) | $2.74B | (m) | $1.65B | $5.58B |
| 2025-06-30 | $15.56B | $2.45B | (m) | $2.75B | (m) | $1.12B | $5.66B |
| 2025-03-31 | $12.73B | $2.23B | (m) | $2.47B | (m) | $697.00M | $2.76B |
| 2024-09-30 | $11.44B | $2.17B | (m) | $2.10B | (m) | $618.10M | $970.30M |
| 2024-06-30 | $11.30B | $2.17B | (m) | $2.12B | (m) | $550.20M | $2.97B |
| 2024-03-31 | $8.77B | $1.67B | (m) | $1.95B | (m) | $293.20M | $2.24B |
| 2023-09-30 | $9.50B | $1.86B | (m) | $1.80B | (m) | $484.60M | -$57.40M |
| 2023-06-30 | $8.31B | $1.81B | $2.36B | $1.93B | (m) | $325.70M | $1.76B |
| 2023-03-31 | $6.96B | $1.63B | $1.99B | $1.75B | (m) | $184.80M | $1.34B |
| 2022-12-31 | (m) | (m) | $2.00B* | (m) | (m) | (m) | (m) |
| 2022-09-30 | $6.94B | $1.58B | $1.80B | $1.61B | (m) | $113.80M | $1.45B |
| 2022-06-30 | $6.49B | $1.43B | $1.78B | $1.63B | (m) | $138.40M | $952.50M |
| 2022-03-31 | $7.81B | $2.07B | $1.61B | $1.56B | (m) | $150.70M | $1.90B |
| 2021-09-30 | $6.77B | $1.43B | $1.71B | $1.58B | (m) | $135.20M | $1.11B |
| 2021-06-30 | $6.74B | $1.95B | $1.66B | $1.69B | (m) | $203.70M | $1.39B |
| 2021-03-31 | $6.81B | $1.88B | $1.67B | $1.58B | (m) | $121.10M | $1.36B |
| 2020-09-30 | $5.74B | $1.33B | $1.47B | $1.57B | (m) | $228.80M | $1.21B |
| 2020-06-30 | $5.50B | $1.22B | $1.39B | $1.45B | (m) | $231.70M | $1.41B |
| 2020-03-31 | $5.86B | $1.22B | $1.39B | $1.55B | (m) | $223.40M | $1.46B |
| 2019-12-31 | $6.11B | $1.28B | (m) | (m) | $3.28B | $167.40M | (m) |
| 2019-09-30 | $5.48B | $1.18B | $1.38B | $1.41B | $2.79B | $151.90M | $1.25B |
| 2019-06-30 | $5.64B | $1.12B | $1.40B | $1.59B | $2.99B | $138.70M | $1.33B |
| 2019-03-31 | $5.09B | $1.14B | $1.23B | $1.52B | $2.75B | $170.00M | $4.24B |
| 2018-12-31 | $5.64B | $1.13B | (m) | (m) | $3.09B | -$189.80M | (m) |
| 2018-09-30 | $5.31B | $1.15B | $1.28B | $1.46B | $2.74B | $247.50M | $1.15B |
| 2018-06-30 | $5.58B | $1.23B | $1.27B | $1.49B | $2.76B | $273.30M | -$259.90M |
| 2018-03-31 | $4.96B | $1.16B | $1.11B | $1.34B | $2.45B | $198.50M | $1.22B |
| 2017-12-31 | $5.41B | $1.19B | (m) | (m) | $3.05B | $1.95B | (m) |
| 2017-09-30 | $4.96B | $1.16B | $1.34B | $1.58B | $2.68B | $29.00M | $555.60M |
| 2017-06-30 | $5.09B | $1.14B | $1.27B | $1.73B | $2.76B | $244.30M | $1.01B |
| 2017-03-31 | $4.51B | $957.70M | $1.26B | $1.57B | $2.58B | $170.30M | -$110.80M |
| 2016-12-31 | $5.76B | (m) | (m) | (m) | $3.24B | $120.20M | $771.80M |
| 2016-09-30 | $5.19B | (m) | $1.24B | $1.57B | $2.80B | $192.70M | $778.00M |
| 2016-06-30 | $5.40B | (m) | $1.34B | $1.62B | $2.96B | $196.80M | $747.70M |
| 2016-03-31 | $4.87B | (m) | $1.22B | $1.47B | $2.69B | $126.70M | $440.10M |
| 2015-12-31 | $5.38B | (m) | (m) | (m) | $3.24B | (m) | $478.40M |
| 2015-09-30 | $4.96B | (m) | $1.14B | $1.58B | $2.72B | $248.10M | $799.70M |
| 2015-06-30 | $4.98B | (m) | $1.17B | $1.64B | $2.80B | $78.90M | $600.80M |
| 2015-03-31 | $4.64B | (m) | $1.04B | $1.52B | $2.56B | $88.40M | $529.50M |
| 2014-12-31 | $5.12B | (m) | (m) | (m) | $2.99B | (m) | $428.50M |
| 2014-09-30 | $4.88B | (m) | $1.24B | $1.67B | $2.92B | $154.90M | $500.60M |
| 2014-06-30 | $4.94B | (m) | $1.20B | $1.66B | $2.86B | $206.90M | $733.50M |
| 2014-03-31 | $4.68B | (m) | $1.11B | $1.48B | $2.59B | $162.90M | $727.90M |
| 2013-12-31 | $5.81B | (m) | (m) | (m) | $3.43B | (m) | $727.50M |
| 2013-09-30 | $5.77B | (m) | $1.38B | $1.65B | $3.03B | $310.30M | $1.20B |
| 2013-06-30 | $5.93B | (m) | $1.33B | $1.87B | $3.20B | $308.70M | $1.21B |
| 2013-03-31 | $5.60B | (m) | $1.35B | $1.65B | $3.00B | $403.10M | $1.55B |
| 2012-12-31 | $5.96B | (m) | (m) | (m) | $3.44B | (m) | $827.20M |
| 2012-09-30 | $5.44B | (m) | $1.34B | $1.76B | $3.10B | $548.10M | $1.33B |
| 2012-06-30 | $5.60B | (m) | $1.32B | $1.93B | $3.25B | $262.10M | $923.60M |
| 2012-03-31 | $5.60B | (m) | $1.15B | $1.85B | $3.00B | $324.20M | $1.01B |
| 2011-09-30 | $6.15B | (m) | $1.28B | $1.92B | (m) | $266.20M | $1.24B |
| 2011-06-30 | $6.25B | (m) | $1.26B | $2.04B | (m) | $334.00M | $1.20B |
| 2011-03-31 | $5.84B | (m) | $1.12B | $1.79B | (m) | $218.00M | $1.06B |
| 2010-09-30 | $5.65B | (m) | $1.22B | $1.69B | (m) | $368.40M | $1.30B |
| 2010-06-30 | $5.75B | (m) | $1.19B | $1.76B | (m) | $387.60M | $1.35B |
| 2010-03-31 | $5.49B | (m) | $1.04B | $1.61B | (m) | $459.70M | $1.25B |
| 2009-09-30 | $5.56B | (m) | $1.12B | $1.70B | (m) | $127.70M | $941.80M |
| 2009-06-30 | $5.29B | (m) | $1.04B | $1.71B | (m) | $309.20M | $1.16B |
| 2009-03-31 | $5.05B | (m) | $947.30M | $1.53B | (m) | $370.30M | $1.31B |
| 2008-09-30 | $5.21B | (m) | $953.00M | $1.65B | (m) | $232.80M | -$465.60M |
| 2008-06-30 | $5.15B | (m) | $951.50M | $1.70B | (m) | $247.50M | $958.80M |
Revenue and expense 6 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $42.77B | $6.84B | (m) | $6.36B | $3.61B | $14.49B |
| 2025-06-30 | $28.29B | $4.67B | (m) | $5.22B | $1.81B | $8.42B |
| 2024-06-30 | $20.07B | $3.84B | (m) | $4.07B | $843.40M | $5.21B |
| 2023-06-30 | $15.27B | $3.43B | $4.34B | $3.67B | $510.50M | $3.11B |
| 2022-06-30 | $14.30B | $3.50B | $3.39B | $3.18B | $289.10M | $2.86B |
| 2021-06-30 | $13.55B | $3.83B | $3.33B | $3.26B | $324.80M | $2.75B |
| 2020-06-30 | $11.36B | $2.44B | $2.78B | $3.00B | $455.10M | $2.87B |
| 2019-06-30 | $10.73B | $2.26B | $2.63B | $3.10B | $308.70M | $5.57B |
| 2018-06-30 | $10.55B | $2.40B | $2.38B | $2.82B | $471.80M | $957.50M |
| 2017-06-30 | $11.05B | $2.92B | $2.53B | $3.30B | $424.50M | $897.20M |
| 2016-06-30 | $10.27B | (m) | $2.56B | $3.10B | $323.50M | $1.19B |
| 2015-06-30 | $9.62B | (m) | $2.21B | $3.16B | $167.30M | $1.13B |
| 2014-06-30 | $9.62B | (m) | $2.30B | $3.15B | $369.80M | $1.46B |
| 2013-06-30 | $11.53B | (m) | $2.68B | $3.52B | $711.80M | $2.75B |
| 2012-06-30 | $11.20B | (m) | $2.47B | $3.78B | $586.30M | $1.93B |
| 2011-06-30 | $12.09B | (m) | $2.38B | $3.83B | $552.00M | $2.25B |
| 2010-06-30 | $11.23B | (m) | $2.23B | $3.37B | $847.30M | $2.60B |
| 2009-06-30 | $10.34B | (m) | $1.99B | $3.24B | $679.50M | $2.47B |
| 2008-06-30 | $9.96B | (m) | $1.83B | $3.25B | $239.50M | $2.02B |
Revenue and expense 9 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2025-09-30 | $45.89B | $7.68B | (m) | $7.96B | $3.46B | $14.00B |
| 2024-09-30 | $31.51B | $6.01B | (m) | $6.17B | $1.46B | $6.18B |
| 2023-09-30 | $24.77B | $5.29B | (m) | $5.48B | $995.10M | $3.05B |
| 2022-09-30 | $21.24B | $5.08B | $5.19B | $4.80B | $402.90M | $4.31B |
| 2021-09-30 | $20.32B | $5.26B | $5.03B | $4.84B | $460.00M | $3.86B |
| 2020-09-30 | $17.10B | $3.76B | $4.25B | $4.57B | $683.90M | $4.08B |
| 2019-09-30 | $16.21B | $3.44B | $4.01B | $4.52B | $460.60M | $6.82B |
| 2018-09-30 | $15.86B | $3.55B | $3.66B | $4.28B | $719.30M | $2.11B |
| 2017-09-30 | $16.71B | $4.51B | $3.87B | $4.88B | $460.50M | $1.45B |
| 2016-09-30 | $15.46B | (m) | $3.79B | $4.66B | $516.20M | $1.97B |
| 2015-09-30 | $14.58B | (m) | $3.35B | $4.73B | $415.40M | $1.93B |
| 2014-09-30 | $14.49B | (m) | $3.55B | $4.82B | $524.70M | $1.96B |
| 2013-09-30 | $17.30B | (m) | $4.06B | $5.17B | $1.02B | $3.96B |
| 2012-09-30 | $16.65B | (m) | $3.81B | $5.54B | $1.13B | $3.26B |
| 2011-09-30 | $18.24B | (m) | $3.67B | $5.75B | $818.20M | $3.49B |
| 2010-09-30 | $16.89B | (m) | $3.45B | $5.06B | $1.22B | $3.90B |
| 2009-09-30 | $15.90B | (m) | $3.11B | $4.94B | $807.20M | $3.41B |
| 2008-09-30 | $15.17B | (m) | $2.78B | $4.90B | $472.30M | $1.56B |
Revenue and expense 12 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2025-12-31 | $65.18B | $11.05B | (m) | $11.09B | $5.09B | $20.64B |
| 2024-12-31 | $45.04B | $8.42B | (m) | $8.59B | $2.09B | $10.59B |
| 2023-12-31 | $34.12B | $7.08B | (m) | $7.40B | $1.31B | $5.24B |
| 2022-12-31 | $28.54B | $6.63B | $7.19B | $6.44B | $561.60M | $6.24B |
| 2021-12-31 | $28.32B | $7.31B | $6.93B | $6.43B | $573.80M | $5.58B |
| 2020-12-31 | $24.54B | $5.48B | $5.98B | $6.12B | $1.04B | $6.19B |
| 2019-12-31 | $22.32B | $4.72B | $5.59B | $6.21B | $628.00M | $8.32B |
| 2018-12-31 | $21.49B | $4.68B | $5.05B | $5.98B | $529.50M | $3.23B |
| 2017-12-31 | $19.97B | $4.45B | $5.10B | $5.98B | $2.39B | -$204.10M |
| 2016-12-31 | $18.31B | $4.16B | $5.04B | $5.84B | $551.40M | $2.74B |
| 2015-12-31 | $19.96B | (m) | $4.80B | $6.53B | $381.60M | $2.41B |
| 2014-12-31 | $19.62B | (m) | $4.73B | $6.62B | $609.80M | $2.39B |
| 2013-12-31 | $23.11B | (m) | $5.53B | $7.13B | $1.20B | $4.68B |
| 2012-12-31 | $22.60B | (m) | $5.28B | $7.51B | $1.32B | $4.09B |
| 2011-12-31 | $24.29B | (m) | $5.02B | $7.88B | $1.00B | $4.35B |
| 2010-12-31 | $23.08B | (m) | $4.88B | $7.05B | $1.46B | $5.07B |
| 2009-12-31 | $21.84B | (m) | $4.33B | $6.89B | $1.03B | $4.33B |
| 2008-12-31 | $20.37B | (m) | $3.84B | $6.63B | $764.30M | -$2.07B |
| 2007-12-31 | $18.63B | (m) | $3.49B | $6.10B | $923.80M | $2.95B |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |